CChubb Read More Chubb Life’s Life Lens is game-changing for advisers2026-09-26 Life Lens by Chubb Life is a 45-second facial scan designed to simplify the life insurance underwriting process…
NNovartis Read More Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies2026-08-22 Novartis Pharma AG Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C…
NNovartis Read More Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies2026-08-19 Novartis Pharma AG Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C…
NNovartis Read More Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases2026-06-06 Novartis Pharma AG New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica,…
NNovartis Read More Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases2026-06-03 Novartis Pharma AG New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica,…
NNovartis Read More Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 20262026-06-03 Novartis Pharma AG New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1…
NNovartis Read More New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength2026-06-03 Novartis Pharma AG Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented…
NNovartis Read More Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases2026-06-01 Novartis Pharma AG New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica,…
NNovartis Read More New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength2026-05-27 Novartis Pharma AG Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented…
NNovartis Read More New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength2026-05-26 Novartis Pharma AG Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented…
NNovartis Read More Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 20262026-03-23 Novartis Pharma AG New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1…
SSwitzerland Read More Ailanto, Cubbit launch sovereign S3 storage in Switzerland2026-02-12 Ailanto has agreed a partnership with Cubbit to offer sovereign, S3-compatible cloud object storage for Swiss enterprises. Hosting…